The invention relates to stable pharmaceutical formulations which are intended to be applied parenterally (liquids or lyophilizates) or topically (gel, ointment or cream) and which comprise different quantities of recombinant gamma- and alpha-interferons in enhancing proportions for the treatment of pathological events that involve malignant or benign non-physiological tissue or organ cell growth.